Introduction {#s1}
============

Major depressive disorder (MDD) is a leading cause of global disability and may affect about 20% during lifetime^1^[^1^](#fn0001){ref-type="fn"}. MDD is a multivariate disorder presenting with a wide range of symptoms and the degree of treatment success varies among patients. About 40% of MDD patients do not respond to current treatments resulting in a high rate of individuals confronted with treatment resistance. In addition, MDD has a high relapse risk and results in premature death by suicide compared to the general population. Therefore, better treatment approaches are needed in this field of medicine, which has become an increasing global concern (Bromet et al., [@B3]).

The first-line therapy for patients with moderate to severe MDD is the administration of antidepressant medications (Chan et al., [@B5]). This treatment is often long and arduous as it can take several weeks before clinical response and efficacy of antidepressant treatment can be determined. Patients who show no response often have to endure one or more additional treatment trials, which may involve dose increase, augmentation with compounds of the same or other drug classes, or switching of antidepressants. Furthermore, approximately 25% of patients who do not improve with the first treatment discontinue their medication (Chan et al., [@B5]). Nonadherence is also a significant predictor of negative outcomes for patients with major affective disorders (Pompili et al., [@B23]). This can lead to high rates of recurrence, hospitalization, functional impairment, active suicidal ideation and suicidal behavior. A history of nonadherence to commonly available antidepressant medications has been associated with a more negative outcome in major depression, increased suicide attempts and enhanced active suicidal ideation. Therefore, improving adherence to antidepressant drugs may generally help clinicians to prevent both major depression and suicidal behaviors. In line with this objective, the identification of biological indicators that could be used in a test to predict treatment response would help to improve outcomes, decrease length of treatment and number of insufficient treatment trials with tremendous impact on lives of patients, healthcare and societal costs.

Recent studies have described the investigation of psychiatric disorders through proteomic analysis of peripheral body fluids, such as blood plasma or serum (Schwarz et al., [@B26]; Stelzhammer et al., [@B29]; van Beveren et al., [@B31]; Chan et al., [@B6]; Jordan et al., [@B14]) and have used proteomic analyses of plasma or serum to identify molecular signatures that can be used to predict response to antipsychotic treatments in patients with schizophrenia (Schwarz et al., [@B27], [@B28]; Tomasik et al., [@B30]). Changes in peripheral body fluids can reflect processes in the brain due to the two-way communication between the brain and periphery and the blood serving as a conduit through the transport of bioactive molecules (Guest et al., [@B9]). Such bioactive molecules include proteins, such as hormones, immune and inflammatory factors, metabolism-related proteins, and transport proteins. As an example, alterations in peripheral cytokine levels can also affect the brain and influence the synthesis, release and reuptake of mood-relevant neurotransmitters (Chan et al., [@B5]). In addition, a number of reports have shown that impairments in hypothalamic-pituitary-adrenal (HPA) axis function and insulin signaling can contribute to inflammation, neurological dysfunctions and memory deficits and circulating levels of growth factors, such as insulin-like growth factor-1 (IGF-1) brain-derived neurotrophic factor (BDNF) and leptin can have influence on mood and cognitive brain function (Chan et al., [@B5]).

Here, we present a pilot study to determine the possibility to detect plasma proteins that can be used for response prediction in MDD patients prior to treatment with antidepressants. This is an open-label naturalistic clinical study, all patients are inpatients who received single or combined treatment with several types of medication. We have used liquid chromatography tandem mass spectrometry (LC-MS/MS) with label-free spectral counting to identify proteins in plasma from these individuals as described in two recent studies of schizophrenia (Martins-de-Souza et al., [@B21]; Saia-Cereda et al., [@B25]). In addition, we were interested to identify proteins showing changes in concentration depending on response to treatment. LC-MS/MS was chosen given the wider range of coverage compared to other platforms, in terms of total numbers of identifiable proteins. In addition, plasma was chosen over the use of serum due to the wider number of clotting factors present in the former (Alsaif et al., [@B1]).

A previous LC-MS/MS profiling study found that the levels of 5 serum proteins could be used to distinguish between MDD and control groups (Lee et al., [@B16]). In addition, a multiplex immunoassay profiling analysis of serum identified several proteins that may be involved in the pathophysiology of depression (Frye et al., [@B7]) and another such study identified a 9-plex panel that could be used to predict response to different antidepressants (Chan et al., [@B4]). The present LC-MS/MS profiling study could provide insights in the molecular pathways affected in both responders and non-responders and thereby lay the groundwork for development of tests for guiding treatment and for detection of novel therapeutics for MDD. It should be noted that the small sample size and preliminary nature of the current study obviates generalization of the findings to wider patient groups.

Materials and methods {#s2}
=====================

Subjects
--------

The study was approved by the Ethics Committee of the Medical Faculty of the Ludwig Maximilians University in Munich, Germany. Plasma was collected from 39 patients suffering from a current a major depressive episode, who participated in the Munich Antidepressant Response Signature (MARS) project (Hennings et al., [@B12]; Table [1](#T1){ref-type="table"}). MARS is an open-label naturalistic clinical study and inpatients admitted to the clinic of the Max Planck Institute of Psychiatry for treatment for depression were included. Details of the study were explained and a written informed consent was obtained from each patient. Patients were diagnosed by trained psychiatrists according to DSM-IV criteria. Only patients with single or recurrent major depression with at least moderate depression severity were included. This required a baseline score of 14 or more on the 21 item version of the Hamilton Depression Rating Scale (HAM-D) (Hamilton, [@B11]). All patients selected for this analysis had a HAM-D score ≥20 at study entry. All patients of this study were not taking any anti-inflammatory or immunosuppresant medications when admitted to the clinic. Only three patients were using nonsteroidal anti-inflammatory drugs (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). No cases of bipolar disorder were included in this analysis. Patients received single or combined treatment with several types of medication including selective serotonin reuptake inhibitors (SSRIs), serotonin--norepinephrine reuptake inhibitor (SNRIs), tricyclic antidepressants (TCA), or dual noradrenergic and serotonergic antidepressants (NASSA, SNRI). Combination therapy of two antidepressants and augmentation with mood stabilizers or second generation antipsychotics was allowed. Treatment outcome was evaluated with weekly HAM-D assessments. Response was defined as a reduction of 50% or more of the baseline HAM-D score after 6 weeks of treatment (T6). Of the 39 patients, 25 were classified as responders and 14 as non-responders according to the criteria set out above. As expected there was a significant difference in T6 HAM-D scores between responders and non-responders (*P* \< 0.001). No significant differences were observed between responders and non-responders with regards to gender (*P* = 1.000; two-sided Fisher\'s exact test), age (*P* = 0.563; Mann Whitney *U*-test), body mass index (*P* = 0.189; Mann-Whitney) or HAM-D scores at baseline (*P* = 0.664). None of the study subjects had diabetes.

###### 

Demographics.

                                                    **Responders**   **Non-responders**   ***P*-value**
  ------------------------------------------------- ---------------- -------------------- ---------------
  Gender (male/female)                              13/11            8/7                  1.000
  Age (years)                                       45.0 ± 17.6      47.5 ± 17.1          0.563
  Body mass index (kg/m^2^)                         23.5 ± 3.2       24.8 ± 2.8           0.189
  Age at disease onset                              36.7 ± 17.9      33.2 ± 16.3          0.555
  No. of previous episodes                          1.5 ± 1.4        5.2 ± 6.9            0.082
  Diagnosis (single episode/recurrent depression)   6/18             3/12                 0.718
  Ham-D T0                                          28.9 ± 6.3       27.9 ± 4.4           0.664
  Ham-D T6                                          7.0 ± 5.3        21.7 + 5.6           *P* \< 0.001

Blood plasma samples
--------------------

Fasting venous blood was collected in the morning in sample tubes containing potassium EDTA immediately after clinical admission and again after 6 weeks of pharmacological treatment. Plasma was separated from blood using the Accuspin System Hystopaque™-1077 (Sigma Aldrich, Taufkirchen, Germany) according to the manufacturer\'s protocol and protein concentrations were determined using the Bradford assay (Bio-Rad; Hercules, CA, USA).

Proteomics
----------

Plasma samples were depleted of high-abundance proteins using the MARS-14 immunodepletion system (Agilent; Wokingham, UK) since these can disrupt resolution of lower abundance proteins in mass spectrometry-based proteomic studies. The depleted flow-through fractions were first treated with 5 mM dithiothreitol (30 min, room temperature) to reduce protein disulfide bonds and then with 10 mM iodoacetamide (30 min, 60°C in the dark) to alkylate the reactive sulfhydryl groups. Each sample was proteolytically digested with trypsin (Promega; Heidelberg, Germany) overnight (1:80 trypsin: protein ratio) for 16 h at 37°C. The resulting peptides were lyophilized and frozen prior to mass spectrometry analyses. Immediately prior to analysis, peptides were dissolved in 0.1% formic acid and injected into the nano-liquid chromatography (LC) system consisting of an autosampler and two-dimensional (2D)-nano high-performance liquid chromatography (HPLC; Eksigent, Dublin, CA, USA), coupled online to an LTQ-Orbitrap XL mass spectrometer (Thermo Scientific; Bremen, Germany). The full detailed description of the nano LC--MS/MS configuration and data analyses can be found in Maccarrone et al. ([@B19]).

For mass spectrometry analysis, samples were measured in data dependent acquisition mode. Survey scans were acquired at a resolution of 60,000 and the 10 most intense signals were fragmented using collision-induced dissociation. The target values and maximum injection times were 10^6^ ions and 100 ms for MS mode and 10^4^ ions and 50 ms for MS/MS mode, respectively. Precursor ions with charge states between 2^+^ and 5^+^ were selected for fragmentation, using a 15 s dynamic exclusion. Raw data were processed using an in-house version of the MASCOT search engine for protein identification and MASCOT Distiller (Matrix Sciences; London, UK) for label-free spectral counting quantification. The cut-off criteria were set at a minimum of 2 peptides for identification and at least 5 MS/MS spectra for quantification to increase the stringency of the process. Differences in protein expression between responders and non-responders (R/NR) at baseline (T0) and between T6 and T0 (T6/T0) were determined using Student\'s *t*-test (*P* \< 0.05). A cut-off of 50% (\>1.50, \<0.66) difference was used as previously established for this workflow (Maccarrone et al., [@B19]). Proteins present at differential levels were classified according to their biological and molecular processes using the Human Protein Reference Database (<http://www.hprd.org>). Note that a maximum ratio of \>5.00 and \<0.20 was used due to limitations of the algorithm employed.

It should also be noted that our objective was to observe common protein signatures of antidepressant response and biological modulation and therefore the type of treatment, e.g., antidepressant class, augmentation, was not taken into consideration.

Results and discussion {#s3}
======================

Identification of proteins at baseline (T0) by comparing responders and non-responders
--------------------------------------------------------------------------------------

Plasma samples taken from patients at baseline (T0) were separated into responders (*n* = 25) and non-responders (*n* = 14), as determined by whether or not they showed a 50% reduction in symptoms at the end of the 6 week treatment period. The proteomic comparison of samples from responder and non-responders led to identification of 29 proteins that showed significant differences (*P* \< 0.05; \> ±50%) in their plasma levels and could therefore be predictive of response (Table [2](#T2){ref-type="table"}). The most prevalent biological processes associated with these proteins were protein metabolism (*n* = 9) and immune response (*n* = 9), followed by energy metabolism (*n* = 3), transport (*n* = 3), cell growth and maintenance (*n* = 3) and cell communication and signaling (*n* = 2). Previous proteomic investigations have implicated these pathways in acute MDD (Chan et al., [@B5]; Stelzhammer et al., [@B29]; Young et al., [@B33]; Liu et al., [@B17]).

###### 

Proteins present at different concentrations in plasma at baseline (T0) associated with a favorable response to subsequent treatment for 6 weeks with antidepressants.

  **UniPort**        **Protein name**                        **Gene**   **R/NR**   **Biological process**             **Molecular class**               **Molecular function**
  ------------------ --------------------------------------- ---------- ---------- ---------------------------------- --------------------------------- ---------------------------------------------
  [P12814](P12814)   Alpha-actinin-1                         ACTN1      \>5.00     Cell growth and maintenance        Cytoskeletal associated protein   Cytoskeletal protein binding
  [P02741](P02741)   C-reactive protein                      CRP        \>5.00     Immune response                    Complement protein                Complement activity
  [P07996](P07996)   Thrombospondin-1                        THBS1      3.52       Cell growth and maintenance        Extracellular matrix protein      Extracellular matrix structural constituent
  [P02671](P02671)   Fibrinogen alpha chain                  FGA        2.98       Protein metabolism                 Coagulation factor                Protein binding
  [Q9BXR6](Q9BXR6)   Complement factor H-related protein 5   CFHR5      2.57       Immune response                    Secreted polypeptide              Complement binding
  [P53367](P53367)   Arfaptin-1                              ARFIP1     2.50       Cell communication and Signaling   Unclassified                      Regulator of G-protein signaling activity
  [P12259](P12259)   Coagulation factor V                    F5         2.50       Protein metabolism                 Coagulation factor                Metal ion binding
  [P36980](P36980)   Complement factor H-related protein 2   CFHR2      2.20       Immune response                    Secreted polypeptide              Molecular function unknown
  [Q9NUI1](Q9NUI1)   Peroxisomal 2,4-dienoyl-CoA reductase   DECR2      1.83       Metabolism                         Enzyme: Reductase                 Catalytic activity
  [P32119](P32119)   Peroxiredoxin-2                         PRDX2      1.75       Metabolism                         Enzyme: Peroxidase                Peroxidase activity
  [Q03591](Q03591)   Complement factor H-related protein 1   CFHR1      1.65       Immune response                    Complement protein                Complement activity
  [P02743](P02743)   Serum amyloid P-component               APCS       1.65       Protein metabolism                 Secreted polypeptide              Binding
  [P60709](P60709)   Actin, cytoplasmic 1                    ACTB       1.63       Cell growth and maintenance        Cytoskeletal protein              Structural constituent of cytoskeleton
  [P02675](P02675)   Fibrinogen beta chain                   FGB        1.55       Protein metabolism                 Coagulation factor                Protein binding
  [O43866](O43866)   CD5 antigen-like                        CD5L       1.52       Immune response                    Secreted polypeptide              Defense/immunity protein activity
  [P00742](P00742)   Coagulation factor X                    F10        0.65       Protein metabolism                 Coagulation factor                Peptidase activity
  [P05155](P05155)   Plasma protease C1 inhibitor            SERPING1   0.64       Protein metabolism                 Protease inhibitor                Protease inhibitor activity
  [O75882](O75882)   Attractin                               ATRN       0.62       Immune response                    Defensin                          Defense/immunity protein activity
  [P22352](P22352)   Glutathione peroxidase 3                GPX3       0.61       Metabolism                         Enzyme: Peroxidase                Peroxidase activity
  [P02760](P02760)   Protein AMBP                            AMBP       0.60       Immune response                    Secreted polypeptide              Defense/immunity protein activity
  [P04114](P04114)   Apolipoprotein B-100                    APOB       0.59       Transport                          Transport/cargo protein           Transporter activity
  [P02753](P02753)   Retinol-binding protein 4               RBP4       0.59       Transport                          Transport/cargo protein           Transporter activity
  [P25311](P25311)   Zinc-alpha-2-glycoprotein               AZGP1      0.58       Immune response                    Adhesion molecule                 Cell adhesion molecule activity
  [P06727](P06727)   Apolipoprotein A-IV                     APOA4      0.47       Transport                          Transport/cargo protein           Transporter activity
  [Q96IY4](Q96IY4)   Carboxypeptidase B2                     CPB2       0.45       Protein metabolism                 Carboxypeptidase                  Carboxypeptidase activity
  [P01023](P01023)   Alpha-2-macroglobulin                   A2M        0.44       Protein metabolism                 Protease inhibitor                Protease inhibitor activity
  [P10643](P10643)   Complement component C7                 C7         0.40       Immune response                    Complement protein                Complement activity
  [O14757](O14757)   Serine/threonine-protein kinase Chk1    CHEK1      \<0.20     Cell communication and signaling   Serine/threonine kinase           Protein serine/threonine kinase activity
  [O43847](O43847)   Nardilysin                              NRD1       \<0.20     Protein metabolism                 Metallo protease                  Metallopeptidase activity

*R/NR, response/non-response ratio. Values were capped at ratios of \>5.0 and \<0.2 due to the ion counting algorithm used. Increased values are shaded in light gray and decreased values are in dark gray*.

The greatest differences were found for alpha-actinin-1, C-reactive protein, thrombospondin-1, fibrinogen alpha chain, complement factor H-related protein 5, coagulation factor V, arfaptin-1 and complement factor H-related protein 2, which were all increased by more than 2-fold in responders. Most of these proteins are related to the innate immune response, inflammation and the coagulation cascade. Effects on protein components of these pathways have been reported previously for MDD patients at risk of suicide (Yang et al., [@B32]) and as markers of treatment resistance (Ruland et al., [@B24]). Furthermore, in a previous study, we found that levels of fibrinogen, a key component of the clotting cascade, may be predictive of antidepressant treatment response (Martins-de-Souza et al., [@B20]). As further evidence for effects on the coagulation cascade, a recent study showed that major depression patients at baseline had an enhanced aggregating response to arachidonic acid and increased levels of clotting factors, such as fibrinogen and factor V (Holzer et al., [@B13]).

Four proteins were by more than 2-fold lower in responders, i.e., apolipoprotein A-IV, carboxypeptidase B2, complement component C7 and serine/threonine-protein kinase Chk1. In addition, three proteins associated with a transport function were lower including apolipoprotein A-IV, apolipoprotein B-100 and retinol-binding protein 4. Previous studies have identified lower levels of all of these proteins in major depression patients (Lopez-Vilchez et al., [@B18]; Frye et al., [@B7]; Lee et al., [@B16]; Ruland et al., [@B24]; Kim et al., [@B15]). In addition, the finding of lower levels of apolipoprotein A-IV in responders is consistent with the findings of a recent study showing that this protein may be a marker of response to different antidepressants (Ruland et al., [@B24]). The changes in the other proteins may represent novel findings requiring further validation.

Identification of protein changes after 6 weeks in responders
-------------------------------------------------------------

Plasma samples taken after 6 weeks of treatment with antidepressants were compared with those taken at baseline (T0) to identify protein changes associated with response to treatment. This led to identification of 43 proteins (Table [3](#T3){ref-type="table"}). Of those proteins, 18 increased more than 2-fold compared to baseline. One of these proteins was putative peptide YY-2 which is consistent with previous studies reporting that peptide YY levels are altered in patients with MDD (Giménez-Palop et al., [@B8]) and bipolar disorder (Haenisch et al., [@B10]). In addition, peptide YY is thought to be involved in regulation of food intake, circadian rhythms, cognition and behavior (Śliwińska-Mossoń et al., [@B22]). Another protein which showed a large increase (\>5-fold) after treatment in responders was serine/threonine-protein kinase Chk1, which may reflect a treatment-normalizing effect since levels were low (R/NR \< 0.20) at baseline. Further studies including follow up validation will be required to corroborate these findings. In addition, two other kinases (serine/threonine-protein kinase Nek1 and microtubule-associated serine/threonine-protein kinase 4) also showed an increase \>2-fold after antidepressant treatment in responders. This could suggest a general effect on kinases involved in a positive response to treatment.

###### 

Proteins present at different concentrations in plasma associated with a favorable response to treatment for 6 weeks with antidepressants.

  **UniPort**        **Protein name**                                                      **Gene**    **T6/T0**   **Biological process**         **Molecular class**                **Molecular function**
  ------------------ --------------------------------------------------------------------- ----------- ----------- ------------------------------ ---------------------------------- ----------------------------------------------
  [Q9NRI6](Q9NRI6)   Putative peptide YY-2                                                 CD5L PYY2   \>5.00      Unknown                        Unclassified                       Molecular function unknown
  [P50135](P50135)   Histamine N-methyltransferase                                         HNMT        \>5.00      Metabolism                     Enzyme: Methyltransferase          Methyltransferase activity
  [Q9BT25](Q9BT25)   HAUS augmin-like complex subunit 8                                    HAUS8       \>5.00      Unknown                        Unclassified                       Molecular function unknown
  [Q9Y2J0](Q9Y2J0)   Rabphilin-3A                                                          RPH3A       \>5.00      Transport                      Membrane transport protein         Auxiliary transport protein activity
  [P37198](P37198)   Nuclear pore glycoprotein p62                                         NUP62       \>5.00      Transport                      Transport/cargo protein            Transporter activity
  [O14757](O14757)   Serine/threonine-protein kinase Chk1                                  CHEK1       \>5.00      Cell communication             Serine/threonine kinase            Protein serine/threonine kinase activity
  [Q8IV08](Q8IV08)   Phospholipase D3                                                      PLD3        \>5.00      Metabolism                     Enzyme: Phospholipase              Phospholipase activity
  [Q9NPP4](Q9NPP4)   NLR family CARD domain-containing protein 4                           NLRC4       \>5.00      Cell communication             Adapter molecule                   Receptor signaling complex scaffold activity
  [O43847](O43847)   **Nardilysin**                                                        NRD1        \>5.00      Protein metabolism             Metallo protease                   Metallopeptidase activity
  [O14727](O14727)   Apoptotic protease-activating factor 1                                APAF1       \>5.00      Cell growth and maintenance    Adapter molecule                   Receptor signaling complex scaffold activity
  [Q96GQ7](Q96GQ7)   Probable ATP-dependent RNA helicase DDX27                             DDX27       \>5.00      Reg. nucleic acid metabolism   RNA helicase                       Helicase activity
  [Q96FV9](Q96FV9)   THO complex subunit 1                                                 THOC1       \>5.00      Reg. nucleic acid metabolism   Transcription regulatory protein   Transcription regulator activity
  [Q96PY6](Q96PY6)   Serine/threonine-protein kinase Nek1                                  NEK1        \>5.00      Cell communication             Serine/threonine kinase            Protein serine/threonine kinase activity
  [Q96KD3](Q96KD3)   Protein FAM71F1                                                       FAM71F1     \>5.00      Unknown                        Unclassified                       Molecular function unknown
  [Q92750](Q92750)   Transcription initiation factor TFIID subunit 4B                      TAF4B       \>5.00      Cell growth and maintenance    Transcription factor               Transcription factor activity
  [P12814](P12814)   **Alpha-actinin-1**                                                   ACTN1       3.02        Cell growth and maintenance    Cytoskeletal associated protein    Cytoskeletal protein binding
  [O15021](O15021)   Microtubule-associated serine/threonine-protein kinase 4              MAST4       2.65        Unknown                        Unclassified                       Molecular function unknown
  [P04075](P04075)   Fructose-bisphosphate aldolase A                                      ALDOA       2.00        Metabolism                     Enzyme: Lyase                      Lyase activity
  [P02751](P02751)   Fibronectin                                                           FN1         1.68        Cell growth and maintenance    Extracellular matrix protein       Extracellular matrix structural constituent
  [P23142](P23142)   Fibulin-1                                                             FBLN1       1.58        Cell growth and maintenance    Extracellular matrix protein       Extracellular matrix structural constituent
  [P08603](P08603)   Complement factor H                                                   CFH         0.67        Immune response                Regulatory/other subunit           Complement binding
  [P04217](P04217)   Alpha-1B-glycoprotein                                                 A1BG        0.58        Unknown                        Secreted polypeptide               Molecular function unknown
  [Q9NUI1](Q9NUI1)   Peroxisomal 2,4-dienoyl-CoA reductase                                 DECR2       0.57        Metabolism                     Enzyme: Reductase                  Catalytic activity
  [Q9UK55](Q9UK55)   Protein Z-dependent protease inhibitor                                SERPINA10   0.43        Protein metabolism             Protease inhibitor                 Protease inhibitor activity
  [Q5SNV9](Q5SNV9)   Uncharacterized protein C1orf167                                      C1orf167    0.40        Unknown                        Unclassified                       Molecular function unknown
  [P46821](P46821)   Microtubule-associated protein 1B                                     MAP1B       0.39        Cell growth and maintenance    Cytoskeletal associated protein    Cytoskeletal protein binding
  [P61769](P61769)   Beta-2-microglobulin                                                  B2M         0.39        Immune response                MHC complex protein                MHC class I receptor activity
  [Q9UKX2](Q9UKX2)   Myosin-2                                                              MYH2        0.26        Cell growth and maintenance    Structural protein                 Structural molecule activity
  [Q9NUV9](Q9NUV9)   GTPase IMAP family member 4                                           GIMAP4      0.25        Cell communication             GTPase                             GTPase activity
  [Q99996](Q99996)   A-kinase anchor protein 9                                             AKAP9       \<0.20      Cell communication             Adapter molecule                   Receptor signaling complex scaffold activity
  [Q9BXL6](Q9BXL6)   Caspase recruitment domain-containing protein 14                      CARD14      \<0.20      Cell growth and maintenance    Enzyme: Phosphotransferase         Catalytic activity
  [Q96PC5](Q96PC5)   Melanoma inhibitory activity protein 2                                MIA2        \<0.20      Unknown                        Unclassified                       Molecular function unknown
  [Q96MW7](Q96MW7)   Tigger transposable element-derived protein 1                         TIGD1       \<0.20      Reg. nucleic acid metabolism   DNA binding protein                DNA binding
  [P46100](P46100)   Transcriptional regulator ATRX                                        ATRX        \<0.20      Reg. nucleic acid metabolism   Transcription regulatory protein   Transcription regulator activity
  [Q96DA0](Q96DA0)   Zymogen granule protein 16 homolog B                                  ZG16B       \<0.20      Unknown                        Unclassified                       Molecular function unknown
  [Q13813](Q13813)   Spectrin alpha chain, non-erythrocytic 1                              SPTAN1      \<0.20      Cell growth and maintenance    Cytoskeletal protein               Structural constituent of cytoskeleton
  [Q9UPN3](Q9UPN3)   Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5            MACF1       \<0.20      Cell growth and maintenance    Structural protein                 Structural molecule activity
  [Q96RL7](Q96RL7)   Vacuolar protein sorting-associated protein 13A                       VPS13A      \<0.20      Protein metabolism             Transport/cargo protein            Transporter activity
  [Q9Y2J2](Q9Y2J2)   Band 4.1-like protein 3                                               EPB41L3     \<0.20      Cell growth and maintenance    Structural protein                 Structural molecule activity
  [Q9NSC5](Q9NSC5)   Homer protein homolog 3                                               HOMER3      \<0.20      Cell communication             Adapter molecule                   Receptor signaling complex scaffold activity
  [P55060](P55060)   Exportin-2                                                            CSE1L       \<0.20      Transport                      Transport/cargo protein            Transporter activity
  [Q09666](Q09666)   Neuroblast differentiation-associated protein AHNAK                   AHNAK       \<0.20      Metabolism                     Unclassified                       Protein binding
  [Q70E73](Q70E73)   Ras-associated and pleckstrin homology domains-containing protein 1   RAPH1       \<0.20      Cell growth and maintenance    Cytoskeletal associated protein    Cytoskeletal protein binding

*T6/T0, the ratio of the protein levels at 6 weeks to the baseline values. Values were capped at ratios of \>5.0 and \<0.2 due to the ion counting algorithm used. Increased values are shaded in light gray and decreased values are in dark gray. Proteins indicated in bold were also identified at baseline*.

Of the remaining proteins, 14 showed a decrease \>2-fold after antidepressant treatment. A large decrease (T6/T0 ratio = 0.26) in plasma mysosin-2 levels was observed in responders after treatment. As mysosin is a component of the cytoskeleton, the decreased levels of this protein may represent a lower level of tissue cellular damage.

Two of the proteins (alpha actinin 1 and nardilysin) altered by the treatment were also present at different levels in the responders at baseline (Table [4](#T4){ref-type="table"}). Alpha actinin-1 showed similar changes in the same direction at T6 as seen at T0 although nardilysin showed opposite changes. Nardilysin is a metalloprotease that cleaves proproteins, such as dynorphin-A, α-neoendorphin, and glucagon at the N-terminus of arginine and lysine residues at sites on the proteins marked by dibasic amino acids. As such nardilysin is involved in proteolytic activation of hormones and neuropeptides involved in brain function. Previous studies have suggested that this endoprotease may be altered in Alzheimer disease, Down syndrome, schizophrenia, mood disorders, alcohol abuse, heroin addiction, and cancer (Bernstein et al., [@B2]).

###### 

Proteins altered in responders (T6-R) and non-responders (T6-NR) after 6 weeks treatment with antidepressants compared with the values at baseline (T0-R/NR).

  **UniProt**        **Protein name**                       **Gene**   **T0--R/NR**   **T6-R**   **T6-NR**   **Biological process**
  ------------------ -------------------------------------- ---------- -------------- ---------- ----------- ----------------------------------
  [P12814](P12814)   Alpha-actinin-1                        ACTN1      \>5.00         3.02       2.32        Cell growth and maintenance
  [P02741](P02741)   C-reactive protein                     CRP        \>5.00                    1.66        Immune response
  [P02671](P02671)   Fibrinogen alpha chain                 FGA        2.98                      1.84        Protein metabolism
  [P02675](P02675)   Fibrinogen beta chain                  FGB        1.55                      1.94        Protein metabolism
  [O75882](O75882)   Attracting                             ATRN       0.62                      2.08        Immune response
  [P04114](P04114)   Apolipoprotein B-100                   APOB       0.59                      0.33        Transport
  [P01023](P01023)   Alpha-2-macroglobulin                  A2M        0.44                      0.64        Protein metabolism
  [O43847](O43847)   Nardilysin                             NRD1       \<0.20         \>5.00     \<0.20      Protein metabolism
  [O14757](O14757)   Serine/threonine-protein kinase Chk1   CHEK1      \<0.20                    3.42        Cell communication and signaling

*Values were capped at ratios of \>5.0 and \<0.2 due to the ion counting algorithm used. Increased values are shaded in light gray and decreased values are in dark gray*.

Identification of proteins changes after 6 weeks in non-responders
------------------------------------------------------------------

After treatment 46 proteins were present at different levels compared to the T0 values in samples from patients who showed a poor clinical response (Table [5](#T5){ref-type="table"}). Of these proteins, 25 were increased. At this stage, it is not possible to determine which of these changes are due to either drug effects, side effects or the poor response and further studies are warranted to determine this. Nine of these proteins were also present at different levels at baseline and the treatment appears to have restored two of these (attractin and serine/threonine-protein kinase Chk1) to normal levels (Table [4](#T4){ref-type="table"}). It should be noted that the increase in serine/threonine-protein kinase Chk1 was smaller than that seen in the responders.

###### 

Proteins present at different concentrations in plasma associated with non-response to treatment with antidepressants after 6 weeks.

  **UniPort**        **Protein name**                                             **Gene**    **T6/T0**   **Biological process**         **Molecular class**                **Molecular function**
  ------------------ ------------------------------------------------------------ ----------- ----------- ------------------------------ ---------------------------------- ----------------------------------------------
  [Q8IV08](Q8IV08)   Phospholipase D3                                             PLD3        \>5.00      Metabolism                     Enzyme: Phospholipase              Phospholipase activity
  [Q9Y5H0](Q9Y5H0)   Protocadherin gamma-A3                                       PCDHGA3     \>5.00      Cell growth and maintenance    Adhesion molecule                  Cell adhesion molecule activity
  [Q9NWV8](Q9NWV8)   BRISC and BRCA1-A complex member 1                           BABAM1      \>5.00      Unknown                        Unclassified                       Molecular function unknown
  [O94913](O94913)   Pre-mRNA cleavage complex 2 protein Pcf11                    PCF11       \>5.00      Reg. nucleic acid metabolism   RNA binding protein                RNA binding
  [P48552](P48552)   Nuclear receptor-interacting protein 1                       NRIP1       \>5.00      Reg. nucleic acid metabolism   Transcription regulatory protein   Transcription regulator activity
  [Q9UK55](Q9UK55)   Protein Z-dependent protease inhibitor                       SERPINA10   \>5.00      Protein metabolism             Protease inhibitor                 Protease inhibitor activity
  [P02751](P02751)   Fibronectin                                                  FN1         4.97        Cell growth and maintenance    Extracellular matrix protein       Extracellular matrix structural constituent
  [Q9UQP3](Q9UQP3)   Tenascin-N                                                   TNN         3.66        Cell growth and maintenance    Extracellular matrix protein       Extracellular matrix structural constituent
  [Q86W92](Q86W92)   Liprin-beta-1                                                PPFIBP1     3.56        Cell communication             Anchor protein                     Cytoskeletal anchoring activity
  [O14757](O14757)   **Serine/threonine-protein kinase Chk1**                     CHEK1       3.42        Cell communication             Serine/threonine kinase            Protein serine/threonine kinase activity
  [Q9BT25](Q9BT25)   HAUS augmin-like complex subunit 8                           HAUS8       2.62        Unknown                        Unclassified                       Molecular function unknown
  [Q9NPP4](Q9NPP4)   NLR family CARD domain-containing protein 4                  NLRC4       2.45        Cell communication             Adapter molecule                   Receptor signaling complex scaffold activity
  [Q1MSJ5](Q1MSJ5)   Centrosome and spindle pole-associated protein 1             CSPP1       2.41        Cell growth and maintenance    Unclassified                       Molecular function unknown
  [P12814](P12814)   **Alpha-actinin-1**                                          ACTN1       2.32        Cell growth and maintenance    Cytoskeletal associated protein    Cytoskeletal protein binding
  [Q9Y490](Q9Y490)   Talin-1                                                      TLN1        2.22        Cell growth and maintenance    Cytoskeletal associated protein    Cytoskeletal protein binding
  [Q92954](Q92954)   Proteoglycan 4                                               PRG4        2.20        Cell growth and maintenance    Cell junction protein              Cell adhesion molecule activity
  [P04278](P04278)   Sex hormone-binding globulin                                 SHBG        2.11        Transport                      Transport/cargo protein            Transporter activity
  [O75882](O75882)   **Attractin**                                                ATRN        2.08        Immune response                Defensin                           Defense/immunity protein activity
  [P02675](P02675)   **Fibrinogen beta chain**                                    FGB         1.94        Protein metabolism             Coagulation factor                 Protein binding
  [P02671](P02671)   **Fibrinogen alpha chain**                                   FGA         1.87        Protein metabolism             Coagulation factor                 Protein binding
  [P26927](P26927)   Hepatocyte growth factor-like protein                        MST1        1.77        Cell communication             Growth factor                      Growth factor activity
  [P02679](P02679)   Fibrinogen gamma chain                                       FGG         1.76        Protein metabolism             Coagulation factor                 Protein binding
  [P02741](P02741)   **C-reactive protein**                                       CRP         1.66        Immune response                Complement protein                 Complement activity
  [Q04756](Q04756)   Hepatocyte growth factor activator                           HGFAC       1.61        Protein metabolism             Serine protease                    Serine-type peptidase activity
  [Q06033](Q06033)   Inter-alpha-trypsin inhibitor heavy chain H3                 ITIH3       1.59        Protein metabolism             Protease inhibitor                 Protease inhibitor activity
  [P01023](P01023)   **Alpha-2-macroglobulin**                                    A2M         0.64        Protein metabolism             Protease inhibitor                 Protease inhibitor activity
  [P61769](P61769)   Beta-2-microglobulin                                         B2M         0.48        Immune response                MHC complex protein                MHC class I receptor activity
  [Q9Y2J2](Q9Y2J2)   Band 4.1-like protein 3                                      EPB41L3     0.44        Cell growth and maintenance    Structural protein                 Structural molecule activity
  [P04114](P04114)   **Apolipoprotein B-100**                                     APOB        0.33        Transport                      Transport/cargo protein            Transporter activity
  [P37198](P37198)   Nuclear pore glycoprotein p62                                NUP62       0.32        Transport                      Transport/cargo protein            Transporter activity
  [Q9Y2J0](Q9Y2J0)   Rabphilin-3A                                                 RPH3A       0.28        Transport                      Membrane transport protein         Auxiliary transport protein activity
  [Q96MW7](Q96MW7)   Tigger transposable element-derived protein 1                TIGD1       0.24        Reg. nucleic acid metabolism   DNA binding protein                DNA binding
  [P55060](P55060)   Exportin-2                                                   CSE1L       0.23        Transport                      Transport/cargo protein            Transporter activity
  [O60934](O60934)   Nibrin                                                       NBN         \<0.20      Cell growth and maintenance    DNA repair protein                 DNA binding
  [Q96PC5](Q96PC5)   Melanoma inhibitory activity protein 2                       MIA2        \<0.20      Unknown                        Unclassified                       Molecular function unknown
  [Q9H3Q3](Q9H3Q3)   Galactose-3-O-sulfotransferase 2                             GAL3ST2     \<0.20      Metabolism                     Enzyme: Sulphotransferase          Sulfotransferase activity
  [O14727](O14727)   Apoptotic protease-activating factor 1                       APAF1       \<0.20      Cell growth and maintenance    Adapter molecule                   Receptor signaling complex scaffold activity
  [Q9UBP8](Q9UBP8)   Kidney-associated antigen 1                                  KAAG1       \<0.20      Immune response                Unclassified                       Molecular function unknown
  [Q8WU90](Q8WU90)   Zinc finger CCCH domain-containing protein 15                ZC3H15      \<0.20      Unknown                        DNA binding protein                DNA binding
  [Q09666](Q09666)   Neuroblast differentiation-associated protein AHNAK          AHNAK       \<0.20      Metabolism                     Unclassified                       Protein binding
  [O43847](O43847)   **Nardilysin**                                               NRD1        \<0.20      Protein metabolism             Metallo protease                   Metallopeptidase activity
  [Q9UPN3](Q9UPN3)   Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5   MACF1       \<0.20      Cell growth and maintenance    Cell growth and maintenance        Structural protein
  [Q13813](Q13813)   Spectrin alpha chain, non-erythrocytic 1                     SPTAN1      \<0.20      Cell growth and maintenance    Cytoskeletal protein               Structural constituent of cytoskeleton
  [O75716](O75716)   Serine/threonine-protein kinase 16                           STK16       \<0.20      Cell communication             Serine/threonine kinase            Protein serine/threonine kinase activity
  [Q9BXL6](Q9BXL6)   Caspase recruitment domain-containing protein 14             CARD14      \<0.20      Cell growth and maintenance    Enzyme: Phosphotransferase         Catalytic activity
  [O15021](O15021)   Microtubule-associated serine/threonine-protein kinase 4     MAST4       \<0.20      Unknown                        Unclassified                       Molecular function unknown

*T6/T0, the ratio of the protein levels at 6 weeks to the baseline values. Values were capped at ratios of \>5.0 and \<0.2 due to the ion counting algorithm used. Increased values are shaded in light gray and decreased values are in dark gray. Proteins indicated in bold were also identified at baseline*.

Comparison of the main biological processes associated with each protein altered in responders and non-responders showed these were mostly similar (Figure [1](#F1){ref-type="fig"}). Eighteen proteins were altered in common which could be due to a common mechanism of action across the different antidepressants. However, more proteins associated with the immune response and protein metabolism were altered in non-responders, suggesting that these pathways are affected more in cases of poor response to treatment. In contrast, more metabolism-related proteins were affected in responder syndicating that a metabolic change might be required for or associated with a favorable response.

![**(A)** Pie chart showing protein levels associated with response or non-response to treatment with antidepressants for 6 weeks. Only gene codes are shown (see tables for the full protein names. **(B)** Histogram showing the major biological processes altered in responders (R) and non-responders (NR).](fnmol-10-00272-g0001){#F1}

Conclusions {#s4}
===========

This is one of only a few mass spectrometry-based proteomics studies, which has attempted to identify a plasma protein fingerprint for prediction of antidepressant treatment response. A recent mass spectrometry profiling study identified a 5-component biomarker panel including apolipoprotein B that was capable of distinguishing MDD and control groups with good accuracy (Lee et al., [@B16]). A multiplex immunoassay profiling study confirmed that this protein may be involved in the pathophysiology of depression (Frye et al., [@B7]). Another multiplex immunoassay study found a 9-component panel predictive of response to different antidepressants and one of these proteins (apolipoprotein A-IV) was also identified in this study (Chan et al., [@B4]).

In our study, LC-MS/MS profiling resulted in identification of 29 proteins at baseline that were present at different levels in those patients who had a subsequent favorable response to treatment. Most of these proteins were associated with either metabolism or immune pathways and 9 of these proteins showed significant changes during the 6-week treatment period. However, we have to note that treatment was not systematically varied but selected according to the psychiatrist (and patient\'s) choices with the aim to continuously optimize antidepressant treatment. There was also no washout period before treatment was started. Thus, the results should be considered as preliminary and warrant further investigation and validation. Nevertheless, it should be stressed that the small sample size analyzed in this study renders the results as preliminary, thus requiring follow up validation work using larger cohorts on repeated occasions. This will enhance generalization of the findings. Furthermore, the different treatment types may influence the response rate and this was not accounted for in this study. Nevertheless, these results represent a promising first step toward the development of a clinical test for biologically informed treatment decisions of psychiatrists and clinicians to improve treatment outcomes and management of patients suffering from MDD. In turn, this should lead to improved patient outcomes and add novel biological targets.
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